Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BI Conducts PIII Trials for 2 Anticancer Agents
January 18, 2010
- Meiji Seika Aims at Becoming “Specialty & Generic”Pharma
January 18, 2010
- Avastin + Chemotherapy Improves PFS in Advanced Breast Cancer Patients
January 18, 2010
- Improvement of Infrastructures Essential to Promote Development of Biomarkers
January 18, 2010
- Mochida, MTPC to Comarket Escitalopram
January 18, 2010
- Tykerb + Herceptin Prolongs OS in Advanced Breast Cancer Patients
January 18, 2010
- Kitasato Ins., Keio Univ. Chosen as Global Clinical Research Centers
January 18, 2010
- Daiichi Sankyo Acquires PharmaForce through Luitpold
January 18, 2010
- Rivaroxaban Reduces Recurrence of Symptomatic VTE: Bayer
January 18, 2010
- Proposed GLs for Oral Hypoglycemic Agents Require Long-Term Studies on All Two-Drug Combinations
January 18, 2010
- Novartis Obtains Diovan's Successor by Acquiring Corthera
January 18, 2010
- KRAS Gene Test Conducted in Only 12% of Patients
January 18, 2010
- Prof. Yamanaka Shows Great Hope for CP-690550 as 4th-Generation Immunosuppressant
January 18, 2010
- AnGes Terminates Cross Licensing Agreement for NF-кB
January 18, 2010
- Fall in the Number of OB/GYN Doctors Halted: Korosho
January 18, 2010
- 1st Product Using Elan's DDS Technology Approved in Japan
January 18, 2010
- Transplacental Administration of Antiarrhythmic Agents Given Conditional Approval
January 18, 2010
- Hatoyama Administration's 1st Budget Proposal for FY2010 Approved by Cabinet
January 18, 2010
- JMA Opposed to Any Decrease in Repeat Consultation Fee Clinics
January 18, 2010
- New Growth Strategy to Focus on Health, Environment, Tourism
January 18, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…